A Comparative Study of MRI and Ultrasound for Detection of Primary Hepatocellular Carcinoma, Body Composition and Risk Factors for Decompensation in Liver Cirrhosis

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMattias Ekstedt

About this trial

DETECT-HCC-ESLD is a prospective multicenter study designed to examine early detection and risk stratification of hepatocellular carcinoma (HCC) in individuals with advanced liver disease. Adults with cirrhosis of different etiologies are enrolled and followed longitudinally with structured clinical assessments and imaging at predefined intervals.

A key objective is to evaluate ultrasound and abbreviated MRI (AMRI) as surveillance modalities for HCC. The study examines detection performance, feasibility, and factors influencing image quality and interpretability.

The protocol also includes the study of body composition, focusing on how variations in adiposity and muscle mass may relate to imaging characteristics, disease progression, and HCC risk.

Longitudinal clinical and imaging data are used to explore prediction models aimed at identifying patients with differing levels of HCC risk. The study records outcomes such as incident HCC, liver-related complications, and mortality to support analyses of disease trajectories.

The DETECT-HCC-ESLD study provides a structured framework for collecting clinical, imaging, and body composition data over time, enabling detailed evaluation of surveillance strategies and risk patterns in advanced liver disease.

Eligibility criteria

Qualifiers

Patients with liver cirrhosis, according to clinical practice. Based on criteria such as elastography, symptoms, biopsy, or radiology.

Age ≥18 years ≤ 84

Written informed consent from the participant

Disqualifiers

Contraindications for MRI (ferrrous material, claustrophobia)

Pregnancy

Diagnosis of primary sclerosing cholangitis (PSC)

Vascular liver disease

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

600 Participants
are grouped into 1 trial group

Sponsors and collaborators

Mattias Ekstedt

Lead sponsor

Linkoeping University

Sponsor institution

Antaros Medical

Collaborator

Amra Medical AB

Collaborator

Region Östergötland

Collaborator

Region Jönköping County

Collaborator

Västra Götalandsregionen

Collaborator

Region Stockholm

Collaborator

Örebro County Council

Collaborator

Uppsala County Council, Sweden

Collaborator

University Hospital, Umeå

Collaborator